Literature DB >> 2507451

Differential response to 1,3-bis (2-chloroethyl)-1-nitrosourea in drug-resistant and -sensitive 9L rat brain tumor cells pretreated with alpha-difluoromethylornithine and 6-thioguanine.

K J Hunter1, D F Deen, L J Marton.   

Abstract

Pretreatment of 9L cells with either alpha-difluoromethylornithine (DFMO), which depletes intracellular levels of polyamines, or 6-thioguanine (6TG), which substitutes for guanine in DNA, potentiates the cytotoxic effects of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU). We examined the effects of these 2 agents in combination on the cytotoxicity of BCNU in sensitive (9L) and resistant (BTRC-19) rat brain tumor cell lines. 9L cells were incubated with 0.2 microM 6TG for 72 hr; during the last 48 hr, 1 mM DFMO was added to cell cultures. The cytotoxicity of BCNU in pretreated cells was increased in an additive manner compared with the effects of each agent alone. Results of experiments in which the BCNU-resistant BTRC-19 cell line was treated similarly showed that only 6TG enhanced BCNU cytotoxicity. Flow cytometry studies showed that these effects are not related to cell-cycle processes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2507451     DOI: 10.1002/ijc.2910440417

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen.

Authors:  M D Prados; M S Edwards; J Rabbitt; K Lamborn; R L Davis; V A Levin
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

Review 2.  Drug resistance in brain tumors.

Authors:  L G Feun; N Savaraj; H J Landy
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

3.  Melding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells.

Authors:  Yoshinori Kajiwara; Sonali Panchabhai; Diane D Liu; Maiying Kong; J Jack Lee; Victor A Levin
Journal:  Technol Cancer Res Treat       Date:  2009-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.